Thoratec Corporation (THOR)
Last closing price (Apr 23 4:00 EDT):
33.52 (-0.89%) ?
Thoratec Corporation engages in the development, manufacture, and marketing of proprietary medical devices used for circulatory support. The companys primary product lines include ventricular assist devices, such as HeartMate II, an implantable left ventricular assist device consisting of a rotary blood pump to provide intermediate and long-term mechanical circulatory support (MCS); and HeartMate XVE, an implantable and pulsatile left ventricular assist device for intermediate and longer-term MCS. Its ventricular assist devices also comprise CentriMag, an extracorporeal full-flow acute surgical support platform that offers support up to 30 days for cardiac and respiratory failure; and PediMag and PediVAS extracorporeal full-flow acute surgical support platforms designed to provide acute surgical support to pediatric patients. In addition, the company provides Paracorporeal Ventricular Assist Device, an external pulsatile ventricular assist device, which provides left, right, and biventricular MCS approved for bridge-to-transplantation (BTT), including home discharge, and post-cardiotomy myocardial recovery; and Implantable Ventricular Assist Device, an implantable and pulsatile ventricular assist device designed to provide left, right, and biventricular MCS approved for BTT comprising home discharge, and post-cardiotomy myocardial recovery. The company sells its products through direct sales force and distributors in the United States and internationally. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
|Jason Mills||Canaccord Genuity||Buy||Oct 31, '13||43.21||Oct 31, '14||-22.43%|
|David Roman||Goldman Sachs||Buy||Oct 14, '13||38.66||46.00||Oct 14, '14||-13.30%|
|Steven Lichtman||Oppenheimer & Co.||Buy||Aug 13, '13||36.65||43.00||Aug 13, '14||17.33%|
|Bruce Nudell||Credit Suisse||Buy||Aug 09, '13||37.38||Aug 09, '14||-10.33%|
|Jayson Bedford||Raymond James||Buy||Aug 02, '13||36.20||40.00||Aug 02, '14||10.50%|
|Jayson Bedford||Raymond James||Buy||Jun 11, '13||30.80||37.00||Jun 11, '14||20.13%|
|Rajeev Jashnani||UBS||Buy||Oct 03, '12||35.82||Oct 03, '13||6.50%|
|Steven Lichtman||Oppenheimer & Co.||Buy||Aug 01, '12||34.00||42.00||Aug 01, '13||-3.56%|
|Steven Lichtman||Oppenheimer & Co.||Buy||May 01, '12||34.50||42.00||May 01, '13||3.68%|
|Charley Jones||Barrington Research||Buy||Feb 12, '12||34.32||38.00||Feb 12, '13||10.72%|
|Charley Jones||Barrington Research||Buy||Nov 02, '11||30.46||36.00||Nov 02, '12||20.22%|
|Steven Lichtman||Oppenheimer & Co.||Buy||May 17, '11||33.09||40.00||May 17, '12||-5.26%|
|Sean Lavin||Lazard Capital Markets||Buy||Apr 17, '11||30.13||34.00||Apr 17, '12||12.84%|
|Jason Mills||Canaccord Genuity||Buy||Jan 11, '11||31.10||43.00||Jan 11, '12||-3.28%|